Results 81 to 90 of about 36,931 (245)

Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification

open access: yesArthritis &Rheumatology, EarlyView.
Objective Proteome‐wide risk models for lupus remain underexplored. We developed classification models to identify lupus from serum proteomic profiles. Methods Patients with lupus and individuals with other autoimmune diseases in the UK Biobank were included.
Mehmet Hocaoǧlu   +2 more
wiley   +1 more source

How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair

open access: yesMolecules, 2017
It is now suggested that the inhibition of biological programs that are associated with the tumor microenvironment may be critical to the diagnostics, prevention and treatment of cancer.
Peter Gál   +8 more
doaj   +1 more source

Mimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatment

open access: yesBMEMat, EarlyView.
This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam   +4 more
wiley   +1 more source

Platelets and galectins.

open access: yesAnnals of translational medicine, 2014
Fil: Schattner, Mirta Ana.
openaire   +2 more sources

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

open access: yesBMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang   +13 more
wiley   +1 more source

Targeting galectin-3 in cancer by novel and unique inhibitors of non-carbohydrate origin

open access: yesMolecular Medicine
The galactoside-binding galectin-3 is a multi-mode promoter in a broad range of cancers, as well as in the pathogenesis of inflammation and fibrosis-associated diseases. It is currently a hotly pursued therapeutic target in those disease areas.
Paulina Sindrewicz-Goral   +8 more
doaj   +1 more source

mRNA Transcriptomics of Galectins Unveils Heterogeneous Organization in Mouse and Human Brain

open access: yesFrontiers in Molecular Neuroscience, 2016
Background: Galectins, a family of non-classically secreted, β-galactoside binding proteins is involved in several brain disorders; however no systematic knowledge on the normal neuroanatomical distribution and functions of galectins exits.
Sebastian John, Rashmi Mishra
doaj   +1 more source

Galectins in hematological malignancies

open access: yesCurrent Opinion in Hematology, 2013
Galectins are a family of lectin molecules that have emerged as key players in inflammation and tumor progresssion by displaying intracellular and extracellular activities. This review describes the recent advances on the role of galectins in hematological neoplasms.Galectin-1 and galectin-3 are the best studied galectins in oncohematology.
Giordano, Mirta Nilda   +2 more
openaire   +3 more sources

Biomarkers of lung congestion and injury in acute heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi   +9 more
wiley   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy